Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | BRS3 | P32247 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405407 | 0.83 | POLB (0.57) | POLBMAPK1CCNE2CCNE1CDK2 | |
| SCHEMBL403274 | 0.82 | ALOX15 (0.50) | POLBMAPK1ALOX15HSD17B10BRS3 | |
| SCHEMBL405327 | 0.81 | KMT2A (0.61) | POLBALDH1A1KDM4E | |
| SCHEMBL400190 | 0.79 | KDM4C (0.52) | CCNE2CCNE1CDK2BRS3MMP13 | |
| SCHEMBL13892327 | 0.78 | TNKS2 (0.57) | POLBHSD17B10ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL398946 | 0.78 | POLB (0.52) | POLBMAPK1ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL4440941 | 0.77 | PARP1 (0.46) | POLBMAPK1ALOX15HSD17B10BRS3 | |
| SCHEMBL405782 | 0.77 | POLB (0.59) | POLBMAPK1ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL3491611 | 0.76 | KMT2A (0.56) | POLBMAPK1CCNE2CCNE1CDK2 | |
| SCHEMBL401595 | 0.76 | MAPT (0.47) | POLBCCNE2CCNE1CDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050739-B1 | QUINAZOLINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-8101624-B2 | Quinazoline derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101557826-A | Therapeutic agent for urinary tract disease | ASKA PHARM CO LTD (JP) | 2009-10-14 | — | — | CN | disclosed |
| EP-2050739-A1 | QUINAZOLINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | POLB 555/4885MAPK1 3757/4885ALOX15 1596/4885 |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | PDE9A, PDE3A, PDE5A | POLB 1464/4885MAPK1 1648/4885ALOX15 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.